Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214
This study is recruiting at 57 US sites in 20 states, according to its ClinicalTrials.gov record last updated .
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pulmonary Disease, Chronic Obstructive
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- GSK Investigational Site · Sheffield, AL
Colorado · 1
- GSK Investigational Site · Aurora, CO
Florida · 19
- GSK Investigational Site · Brooksville, FL
- GSK Investigational Site · Doral, FL
- GSK Investigational Site · Fort Lauderdale, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami Lakes, FL
- GSK Investigational Site · Naples, FL
- GSK Investigational Site · New Port Richey, FL
- GSK Investigational Site · Ocala, FL
- GSK Investigational Site · Orlando, FL
- GSK Investigational Site · Ormond Beach, FL
- GSK Investigational Site · Palmetto Bay, FL
- GSK Investigational Site · Pembroke Pines, FL
- GSK Investigational Site · St. Petersburg, FL
Georgia · 4
- GSK Investigational Site · Adairsville, GA
- GSK Investigational Site · Atlanta, GA
- GSK Investigational Site · Cordele, GA
- GSK Investigational Site · Morrow, GA
Idaho · 1
- GSK Investigational Site · Boise, ID
Illinois · 1
- GSK Investigational Site · Chicago, IL
Louisiana · 3
- GSK Investigational Site · Baton Rouge, LA
- GSK Investigational Site · Lafayette, LA
- GSK Investigational Site · Shreveport, LA
Maine · 1
- GSK Investigational Site · Bangor, ME
Maryland · 1
- GSK Investigational Site · Rockville, MD
Massachusetts · 1
- GSK Investigational Site · Fall River, MA
Michigan · 4
- GSK Investigational Site · Allen Park, MI
- GSK Investigational Site · Detroit, MI
- GSK Investigational Site · Garden City, MI
- GSK Investigational Site · Troy, MI
Nevada · 1
- GSK Investigational Site · Las Vegas, NV
New Jersey · 2
- GSK Investigational Site · Moorestown, NJ
- GSK Investigational Site · Sewell, NJ
New York · 2
- GSK Investigational Site · Mount Kisco, NY
- GSK Investigational Site · New Windsor, NY
North Carolina · 1
- GSK Investigational Site · Shelby, NC
Pennsylvania · 2
- GSK Investigational Site · DuBois, PA
- GSK Investigational Site · Philadelphia, PA
South Carolina · 2
- GSK Investigational Site · Spartanburg, SC
- GSK Investigational Site · Union, SC
Tennessee · 1
- GSK Investigational Site · Knoxville, TN
Texas · 8
- GSK Investigational Site · Austin, TX
- GSK Investigational Site · Dallas, TX
- GSK Investigational Site · El Paso, TX
- GSK Investigational Site · Houston, TX
- GSK Investigational Site · Lampasas, TX
- GSK Investigational Site · Richmond, TX
- GSK Investigational Site · San Antonio, TX
- GSK Investigational Site · Webster, TX
West Virginia · 1
- GSK Investigational Site · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.